WO2001023018A3 - Intranasal delivery system - Google Patents

Intranasal delivery system Download PDF

Info

Publication number
WO2001023018A3
WO2001023018A3 PCT/US2000/026870 US0026870W WO0123018A3 WO 2001023018 A3 WO2001023018 A3 WO 2001023018A3 US 0026870 W US0026870 W US 0026870W WO 0123018 A3 WO0123018 A3 WO 0123018A3
Authority
WO
WIPO (PCT)
Prior art keywords
dose
delivery
administrator
aperture
stream
Prior art date
Application number
PCT/US2000/026870
Other languages
French (fr)
Other versions
WO2001023018A2 (en
Inventor
Steven J Penner
Randal W Sebring
Original Assignee
Heska Corp
Steven J Penner
Randal W Sebring
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heska Corp, Steven J Penner, Randal W Sebring filed Critical Heska Corp
Priority to EP00967128A priority Critical patent/EP1225941A4/en
Priority to CA002386110A priority patent/CA2386110C/en
Priority to US10/089,224 priority patent/US7204822B1/en
Priority to AU77376/00A priority patent/AU774757B2/en
Publication of WO2001023018A2 publication Critical patent/WO2001023018A2/en
Publication of WO2001023018A3 publication Critical patent/WO2001023018A3/en
Priority to US10/941,727 priority patent/US7678087B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0081—Locking means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Abstract

This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as live virus vaccines, to both humans and animals. An axial collapse prevention element (2) to prevent excessive axial deflection of the dose administrator (1) or a dose-location coordinate indicator (3) to facilitate the delivery of a dose to the desired target location may be coupled to the dose administrator (1). An intranasal probe (4) having a force dissemination contact surface (7) may be responsive to a first end of the dose administrator (1). The dose may be delivered from a conformable dose sequestration element (10) through an aperture which penetrates the dose delivery aperture element (5) and the dose may be caused to stream by coupling a stream delivery element (6) to the dose delivery aperture element (5). The force application element (12) which acts upon the dose may be separated from the dose by a fluid dose propellent (13). While the invention may be used for numerous applications, it specifically addresses the difficulties of delivering cold-adapted live equine influenza viruses intranasally to equids.
PCT/US2000/026870 1999-09-29 2000-09-29 Intranasal delivery system WO2001023018A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00967128A EP1225941A4 (en) 1999-09-29 2000-09-29 Intranasal delivery system
CA002386110A CA2386110C (en) 1999-09-29 2000-09-29 Intranasal delivery system
US10/089,224 US7204822B1 (en) 1999-09-29 2000-09-29 Intranasal delivery system
AU77376/00A AU774757B2 (en) 1999-09-29 2000-09-29 Intranasal delivery system
US10/941,727 US7678087B2 (en) 1999-09-29 2004-09-15 Equine intranasal delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/408,584 US6398774B1 (en) 1999-09-29 1999-09-29 Intranasal delivery system
US09/408,584 1999-09-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US40854899A Continuation 1999-09-29 1999-09-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10089244 A-371-Of-International 2000-09-29
US10/941,727 Continuation US7678087B2 (en) 1999-09-29 2004-09-15 Equine intranasal delivery system

Publications (2)

Publication Number Publication Date
WO2001023018A2 WO2001023018A2 (en) 2001-04-05
WO2001023018A3 true WO2001023018A3 (en) 2001-12-06

Family

ID=23616876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026870 WO2001023018A2 (en) 1999-09-29 2000-09-29 Intranasal delivery system

Country Status (5)

Country Link
US (2) US6398774B1 (en)
EP (1) EP1225941A4 (en)
AU (4) AU774757B2 (en)
CA (3) CA2640663C (en)
WO (1) WO2001023018A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6398774B1 (en) * 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US20040039352A1 (en) * 2002-06-28 2004-02-26 Paul Bergeson Nasal dosing device
WO2005014778A2 (en) * 2003-05-15 2005-02-17 The Board Of Regents For Oklahoma State University Dna vaccine expressing ha1 of equine-2 influenza virus
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US9358150B2 (en) 2005-05-13 2016-06-07 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance
US7824436B2 (en) * 2005-05-13 2010-11-02 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling
US8721699B2 (en) 2005-05-13 2014-05-13 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling
ES2496315T3 (en) 2005-10-19 2014-09-18 University Of Florida Research Foundation, Incorporated Materials for the control of respiratory disease in canines
WO2008005577A2 (en) * 2006-07-07 2008-01-10 University Of South Florida Compositions of polyphenols and methods of use
US7749191B2 (en) * 2008-03-20 2010-07-06 Beutlich Lp, Pharmaceuticals Device and method for drug delivery
US8015873B2 (en) * 2008-04-25 2011-09-13 Hall David L Detector housing
US20100174278A1 (en) * 2008-11-07 2010-07-08 Denise Barbut Methods of nasopharyngeal cooling for augmenting coronary perfusion pressure
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN102802717A (en) * 2009-06-19 2012-11-28 贝尼奇尔股份有限公司 Devices for cooling the nasal cavity
CN114010776A (en) 2010-06-09 2022-02-08 疫苗技术股份有限公司 Therapeutic immunization of HIV-infected persons for enhancing antiretroviral therapy
EP2706991B1 (en) 2011-05-11 2021-03-24 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
JP6494527B2 (en) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション Protein antigens that provide protection from pneumococcal colonization and / or disease
CA3030225A1 (en) * 2016-07-20 2018-01-25 Elanco Us Inc. Animal intranasal administration device, systems, and associated methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601077A (en) * 1991-08-07 1997-02-11 Becton, Dickinson And Company Nasal syringe sprayer with removable dose limiting structure
US5720762A (en) * 1996-06-24 1998-02-24 Bass; Lawrence S. Device and method for surgical flap dissection

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950512A (en) 1972-07-25 1976-04-13 Pitman-Moore, Inc. Animal vaccines
US4009258A (en) 1972-09-25 1977-02-22 The Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US3953592A (en) 1973-09-27 1976-04-27 Recherche Et Industrie Therapeutiques (R.I.T.) Live influenza virus vaccines and preparation thereof
US4132775A (en) 1973-12-03 1979-01-02 Richardson-Merrell Inc. Infectious bovine rhinotracheitis virus vaccine and method of preparing and using the same
US4195076A (en) 1974-03-05 1980-03-25 Science Union Et Cie, Societe Francaise De Recherche Medicale Process for the preparation of hemagglutinin from viral sources and methods of utilizing same
FR2262962B1 (en) 1974-03-05 1977-11-04 Science Union & Cie
US4029763A (en) 1974-08-05 1977-06-14 Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing purified neuraminidase antigen and method of using the same
US3962422A (en) 1975-02-18 1976-06-08 Syntex (U.S.A.) Inc. Method for immunizing nursing piglets against transmissible gastroenteritis(TGE) virus
US4053583A (en) 1976-03-01 1977-10-11 Smithkline Corporation Live newcastle disease virus vaccines
US4110427A (en) 1976-04-14 1978-08-29 The Risdon Manufacturing Company Powdered solid aerosol composition and method of manufacture
US4110433A (en) 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
US4512972A (en) 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
US4554159A (en) 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4683137A (en) 1982-04-16 1987-07-28 Cornell Research Foundation, Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
JPS59163313A (en) 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
US4554158A (en) 1983-04-07 1985-11-19 Simonsen Laboratories, Inc. Modified live sendai virus vaccine for administering through an aerosol and method of producing the same
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4767416A (en) * 1986-12-01 1988-08-30 Johnson & Johnson Patient Care, Inc. Spray nozzle for syringe
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5250298A (en) 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof
US4923448A (en) * 1988-12-06 1990-05-08 Mark Anderson Syringe with spray nozzle tip
US5158761A (en) 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5215739A (en) 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5062423A (en) * 1990-02-27 1991-11-05 Minnesota Mining And Manufacturing Company Equine aerosol drug delivery method and apparatus
DE4016126A1 (en) * 1990-04-17 1991-10-24 Coster Tecnologie Speciali Spa DEVICE FOR TRANSNASAL OR ORAL ADMINISTRATION OF MEDICATIONS OR THE LIKE
US5053022A (en) * 1990-06-28 1991-10-01 Mobay Corporation Applicator for intranasal administration of vaccines to horses
IT1244803B (en) * 1990-11-21 1994-09-05 Promo Pack S A SINGLE-DOSE DISPENSER-SPRAYER FOR ENDONASAL ADMINISTRATION OF LIQUID MEDICATIONS.
US5331954A (en) * 1990-12-21 1994-07-26 Novo Nordisk A/S Device for nasal delivery of liquid medications
US5429599A (en) * 1994-05-02 1995-07-04 Heinke; Richard M. Method and means for delivering a pharmaceutical into the nostril of an animal
DE19518810A1 (en) * 1995-05-26 1996-11-28 Bayer Ag Nasal applicator
US5683137A (en) 1996-05-15 1997-11-04 Bright Ideas Group, Inc. Time-out chair/seat
US6398774B1 (en) * 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US6382204B1 (en) * 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601077A (en) * 1991-08-07 1997-02-11 Becton, Dickinson And Company Nasal syringe sprayer with removable dose limiting structure
US5720762A (en) * 1996-06-24 1998-02-24 Bass; Lawrence S. Device and method for surgical flap dissection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1225941A4 *

Also Published As

Publication number Publication date
AU2004218666B2 (en) 2006-08-31
CA2541848A1 (en) 2001-04-05
AU2006236004A1 (en) 2006-12-07
AU2008202537A1 (en) 2008-06-26
US6398774B1 (en) 2002-06-04
CA2640663A1 (en) 2001-04-05
AU2006236004B2 (en) 2008-03-13
CA2386110C (en) 2006-05-30
AU2004218666A1 (en) 2004-11-04
EP1225941A4 (en) 2007-07-11
WO2001023018A2 (en) 2001-04-05
US7204822B1 (en) 2007-04-17
CA2386110A1 (en) 2001-04-05
CA2541848C (en) 2008-12-02
AU7737600A (en) 2001-04-30
AU774757B2 (en) 2004-07-08
CA2640663C (en) 2011-09-13
EP1225941A2 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
WO2001023018A3 (en) Intranasal delivery system
WO2002060412A3 (en) Stabilised polymeric aerosols for pulmonary gene delivery
KR970706018A (en) VACCINE COMPOSITIONS
WO2006006963A3 (en) Aerosol delivery systems and methods
WO2008094219A3 (en) Pulse drug nebulization system, formulations therefore, and methods of use
ATE271383T1 (en) POWDER FORMULATION FOR INHALATION
CY1124878T1 (en) ORODIZED DOSAGE UNIT CONTAINING AN ESTETROL INGREDIENT
PL398576A1 (en) Vaccine preparations, pharmaceutical preparations, attenuated influenza virus, vaccination methods, methods for the prevention of an infectious disease, methods of treatment or prevention of cancers, vaccine compositions and pharmaceutical compositions
EP1476138B8 (en) Modified release formulations of at least one form of tramadol
EP1820853A3 (en) Recombinant influenza viruses for vaccines and gene therapy
WO2004039428A3 (en) Transdermal delivery system for dried particulate or lyophilized medications
DE69818707D1 (en) CHITOSAN AND INFLUENZA-ANTIGEN (S) CONTAINING VACCINE PREPARATIONS FOR ADMINISTRATION BY A MUCOSA
HUP0400264A2 (en) Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers and process for their preparation
BR9809448A (en) Medical aerosol products.
WO2003000018A3 (en) Dopamine agonist formulations for enhanced central nervous system delivery
HUP0203168A2 (en) Compositions for mucosal delivery
EP2272950A3 (en) Defective influenza virus particles
DZ3169A1 (en) Systems and methods for aerosol spraying of pharmaceutical formulations.
JP2013126989A5 (en)
WO2000050050A8 (en) Multiparticulate formulation
BR9714299A (en) Macromolecular compound, processes for the detection of influenza virus and treatment of influenza infection, pharmaceutical composition for this treatment and use of compound
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
NZ602217A (en) Vaccines for influenza
BRPI0414321A (en) high pressure sterilization for final sterilization of pharmaceutical and medical preparations
ATE406152T1 (en) MEDICAL AEROSOL COMPOSITIONS HAVING AN EXCIPIENT COMPOUND CONTAINING AN AMIDE AND/OR ESTER GROUP

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10089224

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2386110

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 77376/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000967128

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000967128

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 77376/00

Country of ref document: AU